11. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn's Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2. (17th August 2016) Authors: Feagan, B; Gasink, C; Lang, Y; Friedman, JR; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Rutgeerts, P; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Tulassay, Z; Seidler, U; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. OC-043 Long term efficacy and safety of ustekinumab for crohn's disease: results from im-uniti long-term extension through 2 years. (17th June 2017) Authors: Sandborn, WJ; Rutgeerts, P; Gasink, C; Jacobstein, D; Gao, L; Johanns, J; Sands, B; Hanauer, S; Targan, S; Ghosh, S; Villiers, WJS de; Colombel, JF; Feagan, BG Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A22 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. OC-045 Efficacy & safety of dose adjustment & delayed response to ustekinumab in moderate–severe crohn's disease patients: results from im-uniti maintenance study. (17th June 2017) Authors: Sands, B; Gasink, C; Jacobstein, D; Gao, L; Johanns, J; Szapary, P; Colombel, J; Targan, S; Ghosh, S; Sandborn, W Journal: Gut Issue: Volume 66(2017)Supplement 2 Page Start: A23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. OC-057 A PH3 Randomised, Multicenter, Double-Blind, Placebo (PBO)-Controlled Study of Ustekinumab (UST) Maintenance Therapy in Moderate–Severe Crohn's Disease (CD) PTS: Results from IM-UNITI. (17th August 2016) Authors: Sandborn, WJ; Feagan, BG; Gasink, C; Jacobstein, D; Gao, L-L; Johanns, J; Sands, B; Hanauer, S; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Lee, SD; Dieleman, L; Katz, S; Rutgeerts, P Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study. (27th May 2021) Authors: Irving, P M; Sands, B E; Hoops, T; Izanec, J L; Gao, L L; Gasink, C; Greenspan, A; Allez, M; Danese, S; Hanauer, S B; Jairath, V; Kuehbacher, T; Lewis, J D; Loftus, E V; Mihaly, E; Panaccione, R; Scherl, E; Shchukina, O; Sandborn, W J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC. (30th January 2023) Authors: Ghosh, S; Feagan, B; Ott, E; Gasink, C; Marano, C; Miao, Y; Sandborn, W; Danese, S; Abreu, M; Sands, B Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i55 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. P186 Outcomes of maintenance ustekinumab therapy for Crohn's disease based on inflammatory burden: A post-hoc analysis of the UNITI trials. (16th January 2018) Authors: Ghosh, S; Sattin, B; Tornatore, V; Gasink, C; Gao, L -L; Sloan, S; Rutgeerts, P; Sands, B; Hanauer, S; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn's disease studies. (16th January 2018) Authors: Colombel, J -F; Gasink, C; Oortwijn, A; van Kruchten, R; Sloan, S; Laliman, V; Rutgeerts, P; Ghosh, S; Sandborn, W; Feagan, B; Sands, B Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S243 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. P313 Steroid and opioid use among Crohn's patients before and after initiation of ustekinumab. (16th January 2018) Authors: Obando, C; Woodruff, K; Muser, E; Gasink, C; Hoops, T; Slaton, T; Kozma, C M Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. P317 Characterisation of patients with delayed response to ustekinumab for Crohn's disease. (25th January 2019) Authors: Sands, B E; Oortwijn, A; Rijnders, N; Izanec, J; Gasink, C; Jacobstein, D; Adedokun, O J; Ma, T; Gao, L-L; Colombel, J-F; Targan, S; Ghosh, S; Sandborn, W J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗